Our Opinion

Conduit Pharmaceuticals Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following press release that they exploit animals for product testing.

“Preclinical studies of up to 12-month duration have been performed.  These showed a potent glucose lowering effect in healthy animals. In addition to the severe hypoglycemia observed at higher doses, both Wallerian type nerve degeneration and skeletal muscle fibre degeneration were observed. Additional changes, also considered secondary to hypoglycaemia, were seen in the liver including the loss of hepatocellular glycogen.” Read the following article

Company Description

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto’s thyroiditis and Grave’s disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Company Website: https://www.conduitpharma.com